Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2023

Open Access 01-12-2023 | NSCLC | Review

PRC2 mediated KLF2 down regulation: a therapeutic and diagnostic axis during tumor progression

Authors: Negin Taghehchian, Amirhosein Maharati, Iman Akhlaghipour, Amir Sadra Zangouei, Meysam Moghbeli

Published in: Cancer Cell International | Issue 1/2023

Login to get access

Abstract

Surgery and chemo-radiotherapy are used as the common first-line treatment options in many cancers. However, tumor relapse is observed in many cancer patients following such first-line treatments. Therefore, targeted therapy according to the molecular cancer biology can be very important in reducing tumor recurrence. In this regard, a wide range of monoclonal antibodies against the growth factors and their receptors can offer more targeted treatment in cancer patients. However, due to the importance of growth factors in the normal biology of body cells, side effects can also be observed following the application of growth factor inhibitors. Therefore, more specific factors should be introduced as therapeutic targets with less side effects. Krüppel-like factors 2 (KLF2) belongs to the KLF family of transcription factors that are involved in the regulation of many cellular processes. KLF2 deregulations have been also reported during the progression of many tumors. In the present review we discussed the molecular mechanisms of KLF2 during tumor growth and invasion. It has been shown that the KLF2 as a tumor suppressor is mainly inhibited by the non-coding RNAs (ncRNAs) through the polycomb repressive complex 2 (PRC2) recruitment. This review is an effective step towards introducing the KLF2 as a suitable diagnostic and therapeutic target in cancer patients.
Literature
1.
Wei G, Wang Y, Yang G, Wang Y, Ju R. Recent progress in nanomedicine for enhanced cancer chemotherapy. Theranostics. 2021;11(13):6370–92.PubMedPubMedCentral
2.
Siegel RL, Miller KD, Fuchs HE, Jemal A, Cancer Statistics. 2021. CA Cancer J Clin. 2021;71(1):7–33.
3.
4.
Chabner BA, Roberts TG Jr, Timeline. Chemotherapy and the war on cancer. Nat Rev Cancer. 2005;5(1):65–72.PubMed
5.
Moghbeli M. MicroRNAs as the critical regulators of cisplatin resistance in ovarian cancer cells. J Ovarian Res. 2021;14(1):127.PubMedPubMedCentral
6.
Zangouei AS, Alimardani M, Moghbeli M. MicroRNAs as the critical regulators of doxorubicin resistance in breast tumor cells. Cancer Cell Int. 2021;21(1):213.PubMedPubMedCentral
7.
Perez-Herrero E, Fernandez-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52–79.PubMed
8.
Maston GA, Evans SK, Green MR. Transcriptional regulatory elements in the human genome. Annu Rev Genomics Hum Genet. 2006;7:29–59.PubMed
9.
Yao S, Fan LY, Lam EW. The FOXO3-FOXM1 axis: a key cancer drug target and a modulator of cancer drug resistance. Semin Cancer Biol. 2018;50:77–89.PubMedPubMedCentral
10.
Preiss A, Rosenberg UB, Kienlin A, Seifert E, Jäckle H. Molecular genetics of Krüppel, a gene required for segmentation of the Drosophila embryo. Nature. 1985;313(5997):27–32.PubMed
11.
Miller I, Bieker JJ. A novel, erythroid cell-specific murine transcription factor that binds to the CACCC element and is related to the Krüppel family of nuclear proteins. Mol Cell Biol. 1993;13(5):2776–86.PubMedPubMedCentral
12.
Bialkowska AB, Yang VW, Mallipattu SK. Krüppel-like factors in mammalian stem cells and development. Development. 2017;144(5):737–54.PubMedPubMedCentral
13.
Xie P, Tang Y, Shen S, Wang Y, Xing G, Yin Y, et al. Smurf1 ubiquitin ligase targets Kruppel-like factor KLF2 for ubiquitination and degradation in human lung cancer H1299 cells. Biochem Biophys Res Commun. 2011;407(1):254–9.PubMed
14.
Li Y, Tu S, Zeng Y, Zhang C, Deng T, Luo W, et al. KLF2 inhibits TGF-β-mediated cancer cell motility in hepatocellular carcinoma. Acta Biochim Biophys Sin. 2020;52(5):485–94.PubMed
15.
Huang M-D, Chen W-M, Qi F-Z, Sun M, Xu T-P, Ma P, et al. Long non-coding RNA TUG1 is up-regulated in hepatocellular carcinoma and promotes cell growth and apoptosis by epigenetically silencing of KLF2. Mol Cancer. 2015;14(1):1–12.
16.
Dejana E. The role of wnt signaling in physiological and pathological angiogenesis. Circul Res. 2010;107(8):943–52.
17.
Phng L-K, Potente M, Leslie JD, Babbage J, Nyqvist D, Lobov I, et al. Nrarp coordinates endothelial notch and wnt signaling to control vessel density in angiogenesis. Dev Cell. 2009;16(1):70–82.PubMedPubMedCentral
18.
19.
Nie F, Yu X, Huang M, Wang Y, Xie M, Ma H, et al. Long noncoding RNA ZFAS1 promotes gastric cancer cells proliferation by epigenetically repressing KLF2 and NKD2 expression. Oncotarget. 2017;8(24):38227.PubMed
20.
Li X, Li Z, Liu Z, Xiao J, Yu S, Song Y, Correction. Long non-coding RNA DLEU1 predicts poor prognosis of gastric cancer and contributes to cell proliferation by epigenetically suppressing KLF2. Cancer Gene Ther. 2022;29(6):873.PubMed
21.
Zhang W, Levi L, Banerjee P, Jain M, Noy N. Kruppel-like factor 2 suppresses mammary carcinoma growth by regulating retinoic acid signaling. Oncotarget. 2015;6(34):35830.PubMedPubMedCentral
22.
Zou K, Lu X, Ye K, Wang C, You T, Chen J. Kruppel-like factor 2 promotes cell proliferation in hepatocellular carcinoma through up-regulation of c-myc. Cancer Biol Ther. 2016;17(1):20–6.PubMedPubMedCentral
23.
Li H, Cai Q, Wu H, Vathipadiekal V, Dobbin ZC, Li T, et al. SUZ12 promotes human epithelial ovarian Cancer by suppressing apoptosis via silencing HRKSUZ12 promotes EOC via silencing HRK. Mol Cancer Res. 2012;10(11):1462–72.PubMedPubMedCentral
24.
Martín-Pérez D, Sánchez E, Maestre L, Suela J, Vargiu P, Di Lisio L, et al. Deregulated expression of the polycomb-group protein SUZ12 target genes characterizes mantle cell lymphoma. Am J Pathol. 2010;177(2):930–42.PubMedPubMedCentral
25.
Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell. 2010;39(5):761–72.PubMedPubMedCentral
26.
Xia R, Jin F-y, Lu K, Wan L, Xie M, Xu T-p, et al. SUZ12 promotes gastric cancer cell proliferation and metastasis by regulating KLF2 and E-cadherin. Tumor Biology. 2015;36(7):5341–51.PubMed
27.
Lee MG, Wynder C, Cooch N, Shiekhattar R. An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature. 2005;437(7057):432–5.PubMed
28.
Shi Y-J, Matson C, Lan F, Iwase S, Baba T, Shi Y. Regulation of LSD1 histone demethylase activity by its associated factors. Mol Cell. 2005;19(6):857–64.PubMed
29.
Adamo A, Sesé B, Boue S, Castaño J, Paramonov I, Barrero MJ, et al. LSD1 regulates the balance between self-renewal and differentiation in human embryonic stem cells. Nat Cell Biol. 2011;13(6):652–9.PubMed
30.
McDonald OG, Wu H, Timp W, Feinberg AP. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat Struct Mol Biol. 2011;18(8):867–74.PubMedPubMedCentral
31.
Lv T, Yuan D, Miao X, Lv Y, Zhan P, Shen X, et al. Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer. PLoS ONE. 2012;7(4):e35065.PubMedPubMedCentral
32.
Fang R, Xu J, Lin H, Xu X, Tian F. The histone demethylase lysine-specific demethylase-1–mediated epigenetic silence of KLF2 contributes to gastric cancer cell proliferation, migration, and invasion. Tumor Biology. 2017;39(4):1010428317698356.PubMed
33.
Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15(1):7–21.PubMed
34.
Payer B, Lee JT. Coupling of X-chromosome reactivation with the pluripotent stem cell state. RNA Biol. 2014;11(7):798–807.PubMedPubMedCentral
35.
Flynn RA, Chang HY. Long noncoding RNAs in cell-fate programming and reprogramming. Cell Stem Cell. 2014;14(6):752–61.PubMedPubMedCentral
36.
Fatima R, Akhade VS, Pal D, Rao SM. Long noncoding RNAs in development and cancer: potential biomarkers and therapeutic targets. Mol Cell Ther. 2015;3(1):1–19.
37.
Khalili-Tanha G, Moghbeli M. Long non-coding RNAs as the critical regulators of doxorubicin resistance in tumor cells. Cell Mol Biol Lett. 2021;26(1):39.PubMedPubMedCentral
38.
Zhang F, Zhang L, Zhang C. Long noncoding RNAs and tumorigenesis: genetic associations, molecular mechanisms, and therapeutic strategies. Tumor Biology. 2016;37(1):163–75.PubMed
39.
Rahmani Z, Mojarrad M, Moghbeli M. Long non-coding RNAs as the critical factors during tumor progressions among iranian population: an overview. Cell Biosci. 2020;10:6.PubMedPubMedCentral
40.
Xu Q, Qiao S, Liu L, Xu J, Yang L, Chen X, et al. LINC00202 attenuates the progression of gastric cancer via suppressing expression level of KLF2. J BU ON: Official J Balkan Union Oncol. 2021;26(2):506–12.
41.
Wang L, Meng D, Wang Y, Hu J. Long non-coding RNA LINC01296 promotes esophageal squamous cell carcinoma cell proliferation and invasion by epigenetic suppression of KLF2. Am J Cancer Res. 2018;8(10):2020.PubMedPubMedCentral
42.
Yuan X, Li J, Cao Y, Jie Z, Zeng Y. Long non-coding RNA AFAP1-AS1 promotes proliferation and migration of gastric cancer by downregulating KLF2. Eur Rev Med Pharmacol Sci. 2020;24:673–80.PubMed
43.
Forghanifard MM, Rad A, Farshchian M, Khaleghizadeh M, Gholamin M, Moghbeli M, et al. TWIST1 upregulates the MAGEA4 oncogene. Mol Carcinog. 2017;56(3):877–85.PubMed
44.
Hamidi AA, Khalili-Tanha G, Nasrpour Navaei Z, Moghbeli M. Long non-coding RNAs as the critical regulators of epithelial mesenchymal transition in colorectal tumor cells: an overview. Cancer Cell Int. 2022;22(1):71.PubMedPubMedCentral
45.
Zlotnik A. New insights on the role of CXCR4 in cancer metastasis. J Pathology: J Pathological Soc Great Br Irel. 2008;215(3):211–3.
46.
Yin H, Wang Y, Chen W, Zhong S, Liu Z, Zhao J. Drug-resistant CXCR4-positive cells have the molecular characteristics of EMT in NSCLC. Gene. 2016;594(1):23–9.PubMed
47.
Qin SY, Li B, Chen M, Qin MQ, Liu JM, Lv QL. MiR-32‐5p promoted epithelial‐to‐mesenchymal transition of oral squamous cell carcinoma cells via regulating the KLF2/CXCR4 pathway. Kaohsiung J Med Sci. 2022;38(2):120–8.PubMed
48.
Yao H, Ashihara E, Maekawa T. Targeting the Wnt/β-catenin signaling pathway in human cancers. Expert Opin Ther Targets. 2011;15(7):873–87.PubMed
49.
Huang L, Wu R-L, Xu A-M. Epithelial-mesenchymal transition in gastric cancer. Am J Translational Res. 2015;7(11):2141.
50.
Liu Z, Chen Z, Fan R, Jiang B, Chen X, Chen Q, et al. Over-expressed long noncoding RNA HOXA11-AS promotes cell cycle progression and metastasis in gastric cancer. Mol Cancer. 2017;16(1):1–9.
51.
Zangouei AS, Barjasteh AH, Rahimi HR, Mojarrad M, Moghbeli M. Role of tyrosine kinases in bladder cancer progression: an overview. Cell Commun Signal. 2020;18(1):127.PubMedPubMedCentral
52.
Moghbeli M, Makhdoumi Y, Soltani Delgosha M, Aarabi A, Dadkhah E, Memar B, et al. ErbB1 and ErbB3 co-over expression as a prognostic factor in gastric cancer. Biol Res. 2019;52(1):2.PubMedPubMedCentral
53.
Navaei ZN, Khalili-Tanha G, Zangouei AS, Abbaszadegan MR, Moghbeli M. PI3K/AKT signaling pathway as a critical regulator of cisplatin response in tumor cells. Oncol Res. 2021;29(4):235–50.PubMed
54.
Wang C, Li L, Duan Q, Wang Q, Chen J. Krüppel-like factor 2 suppresses human gastric tumorigenesis through inhibiting PTEN/AKT signaling. Oncotarget. 2017;8(59):100358.PubMedPubMedCentral
55.
Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang P, et al. CUL4A induces epithelial–mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res. 2014;74(2):520–31.PubMed
56.
Ren W, Sun Z, Zeng Q, Han S, Zhang Q, Jiang L. Aberrant expression of CUL4A is associated with IL-6/STAT3 activation in colorectal cancer progression. Arch Med Res. 2016;47(3):214–22.PubMed
57.
Sharma P, Nag A. CUL4A ubiquitin ligase: a promising drug target for cancer and other human diseases. Open Biology. 2014;4(2):130217.PubMedPubMedCentral
58.
Lian Y, Yan C, Xu H, Yang J, Yu Y, Zhou J, et al. A novel lncRNA, LINC00460, affects cell proliferation and apoptosis by regulating KLF2 and CUL4A expression in colorectal cancer. Mol Therapy-Nucleic Acids. 2018;12:684–97.
59.
Lian Y, Yan C, Ding J, Xia R, Ma Z, Hui B, et al. A novel lncRNA, LL22NC03-N64E9. 1, represses KLF2 transcription through binding with EZH2 in colorectal cancer. Oncotarget. 2017;8(35):59435.PubMedPubMedCentral
60.
Joerger AC, Fersht AR. The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches. Annu Rev Biochem. 2016;85:375–404.PubMed
61.
Labuschagne CF, Zani F, Vousden KH. Control of metabolism by p53–cancer and beyond. Biochim et Biophys Acta (BBA)-Reviews Cancer. 2018;1870(1):32–42.
62.
Ghosh-Choudhury N, Mandal CC, Ghosh-Choudhury N, Choudhury GG. Simvastatin induces derepression of PTEN expression via NFκB to inhibit breast cancer cell growth. Cell Signal. 2010;22(5):749–58.PubMedPubMedCentral
63.
Fang Z, Tang Y, Fang J, Zhou Z, Xing Z, Guo Z, et al. Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway. PLoS ONE. 2013;8(5):e62823.PubMedPubMedCentral
64.
Cho SJ, Kim JS, Kim JM, Lee JY, Jung HC, Song IS. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer. 2008;123(4):951–7.PubMed
65.
Gopalan A, Yu W, Sanders BG, Kline K. Simvastatin inhibition of mevalonate pathway induces apoptosis in human breast cancer cells via activation of JNK/CHOP/DR5 signaling pathway. Cancer Lett. 2013;329(1):9–16.PubMed
66.
Lu L, Huang W, Hu W, Jiang L, Li Y, Wu X, et al. Kruppel-like factor 2 mediated anti-proliferative and anti-metastasis effects of simvastatin in p53 mutant colon cancer. Biochem Biophys Res Commun. 2019;511(4):772–9.PubMed
67.
Xu M, Chen X, Lin K, Zeng K, Liu X, Pan B, et al. The long noncoding RNA SNHG1 regulates colorectal cancer cell growth through interactions with EZH2 and miR-154-5p. Mol Cancer. 2018;17(1):1–16.
68.
Ding J, Xie M, Lian Y, Zhu Y, Peng P, Wang J, et al. Long noncoding RNA HOXA-AS2 represses P21 and KLF2 expression transcription by binding with EZH2, LSD1 in colorectal cancer. Oncogenesis. 2017;6(1):e288–e.PubMedPubMedCentral
69.
Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721–32.PubMed
70.
Shen G, Li X, Jia Y-f, Piazza GA, Xi Y. Hypoxia-regulated microRNAs in human cancer. Acta Pharmacol Sin. 2013;34(3):336–41.PubMedPubMedCentral
71.
Tian Q, Xue Y, Zheng W, Sun R, Ji W, Wang X, et al. Overexpression of hypoxia-inducible factor 1α induces migration and invasion through notch signaling. Int J Oncol. 2015;47(2):728–38.PubMed
72.
Wang Y, Liu Y, Malek SN, Zheng P, Liu Y. Targeting HIF1α eliminates cancer stem cells in hematological malignancies. Cell Stem Cell. 2011;8(4):399–411.PubMedPubMedCentral
73.
Meng RD, Shelton CC, Li Y-M, Qin L-X, Notterman D, Paty PB, et al. γ-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res. 2009;69(2):573–82.PubMedPubMedCentral
74.
Wang H-G, Cao B, Zhang L-X, Song N, Li H, Zhao W-Z, et al. KLF2 inhibits cell growth via regulating HIF-1α/Notch-1 signal pathway in human colorectal cancer HCT116 cells. Oncol Rep. 2017;38(1):584–90.PubMed
75.
Zeng Z, Li Y, Pan Y, Lan X, Song F, Sun J, et al. Cancer-derived exosomal mir-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis. Nat Commun. 2018;9(1):1–14.
76.
Wu J, Lingrel JB. KLF2 inhibits Jurkat T leukemia cell growth via upregulation of cyclin-dependent kinase inhibitor p21WAF1/CIP1. Oncogene. 2004;23(49):8088–96.PubMed
77.
Wang F, Zhu Y, Huang Y, McAvoy S, Johnson WB, Cheung TH, et al. Transcriptional repression of WEE1 by Kruppel-like factor 2 is involved in DNA damage-induced apoptosis. Oncogene. 2005;24(24):3875–85.PubMed
78.
Zhang X, Srinivasan SV, Lingrel JB. WWP1-dependent ubiquitination and degradation of the lung Krüppel-like factor, KLF2. Biochem Biophys Res Commun. 2004;316(1):139–48.PubMed
79.
Zhu H, Kavsak P, Abdollah S, Wrana JL, Thomsen GH. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature. 1999;400(6745):687–93.PubMed
80.
Wang H-R, Zhang Y, Ozdamar B, Ogunjimi AA, Alexandrova E, Thomsen GH, et al. Regulation of cell polarity and protrusion formation by targeting RhoA for degradation. Science. 2003;302(5651):1775–9.PubMed
81.
Morén A, Imamura T, Miyazono K, Heldin C-H, Moustakas A. Degradation of the tumor suppressor Smad4 by WW and HECT domain ubiquitin ligases. J Biol Chem. 2005;280(23):22115–23.PubMed
82.
Yin L, Wang J-p, Xu T-p, Chen W-m, Huang M-d, Xia R, et al. Downregulation of Kruppel-like factor 2 is associated with poor prognosis for nonsmall-cell lung cancer. Tumor Biology. 2015;36(4):3075–84.PubMed
83.
Zang C, Nie F-q, Wang Q, Sun M, Li W, He J, et al. Long non-coding RNA LINC01133 represses KLF2, P21 and E-cadherin transcription through binding with EZH2, LSD1 in non small cell lung cancer. Oncotarget. 2016;7(10):11696.PubMedPubMedCentral
84.
Jiang W, Xu X, Deng S, Luo J, Xu H, Wang C, et al. Methylation of kruppel-like factor 2 (KLF2) associates with its expression and non-small cell lung cancer progression. Am J Translational Res. 2017;9(4):2024.
85.
Sun B, Zhao J, Shao Z. MiR-572 promotes the development of non-small cell lung cancer by targeting KLF2. Eur Rev Med Pharmacol Sci. 2022;26(9):3083–90.PubMed
86.
Völkel P, Dupret B, Le Bourhis X, Angrand P-O. Diverse involvement of EZH2 in cancer epigenetics. Am J Translational Res. 2015;7(2):175.
87.
88.
Sun C-C, Li S-J, Li G, Hua R-X, Zhou X-H, Li D-J. Long intergenic noncoding RNA 00511 acts as an oncogene in non–small-cell lung cancer by binding to EZH2 and suppressing p57. Mol Therapy-Nucleic Acids. 2016;5:e385.
89.
Abe Y, Ohsugi M, Haraguchi K, Fujimoto J, Yamamoto T. LATS2–Ajuba complex regulates γ-tubulin recruitment to centrosomes and spindle organization during mitosis. FEBS Lett. 2006;580(3):782–8.PubMed
90.
McPherson JP, Tamblyn L, Elia A, Migon E, Shehabeldin A, Matysiak-Zablocki E, et al. Lats2/Kpm is required for embryonic development, proliferation control and genomic integrity. EMBO J. 2004;23(18):3677–88.PubMedPubMedCentral
91.
Li W, Sun M, Zang C, Ma P, He J, Zhang M, et al. Upregulated long non-coding RNA AGAP2-AS1 represses LATS2 and KLF2 expression through interacting with EZH2 and LSD1 in non-small-cell lung cancer cells. Cell Death Dis. 2016;7(5):e2225–e.PubMedPubMedCentral
92.
Zhu F, Zhang S, Wang L, Wu W, Zhao H. LINC00511 promotes the progression of non-small cell lung cancer through downregulating LATS2 and KLF2 by binding to EZH2 and LSD1. Eur Rev Med Pharmacol Sci. 2019;23(19):8377–90.PubMed
93.
Fang J, Sun C-C, Gong C. Long noncoding RNA XIST acts as an oncogene in non-small cell lung cancer by epigenetically repressing KLF2 expression. Biochem Biophys Res Commun. 2016;478(2):811–7.PubMed
94.
Han F, Huang D, Meng J, Chu J, Wang M, Chen S. Mir-126‐5p enhances radiosensitivity of lung adenocarcinoma cells by inhibiting EZH2 via the KLF2/BIRC axis. J Cell Mol Med. 2022;26(9):2529–42.PubMedPubMedCentral
95.
Lu J. The Warburg metabolism fuels tumor metastasis. Cancer Metastasis Rev. 2019;38(1):157–64.PubMed
96.
Grasmann G, Smolle E, Olschewski H, Leithner K. Gluconeogenesis in cancer cells–repurposing of a starvation-induced metabolic pathway? Biochim et Biophys Acta (BBA)-Reviews Cancer. 2019;1872(1):24–36.
97.
Matés JM, Campos-Sandoval JA, Márquez J. Glutaminase isoenzymes in the metabolic therapy of cancer. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2018;1870(2):158–64.
98.
Scalise M, Pochini L, Galluccio M, Console L, Indiveri C. Glutamine transport and mitochondrial metabolism in cancer cell growth. Front Oncol. 2017;7:306.PubMedPubMedCentral
99.
Xiao S, Jin-Xiang Y, Long T, Xiu-Rong L, Hong G, Jie-Cheng Y, et al. Kruppel-like factor 2 disturb non-small cell lung cancer energy metabolism by inhibited glutamine consumption. J Pharm Pharmacol. 2020;72(6):843–51.PubMed
100.
Shi Y, Sun X, He X. Overexpression of Aristaless-like Homeobox-4 inhibits proliferation, invasion, and EMT in hepatocellular carcinoma cells. Oncol Res. 2017;25(1):11.PubMedPubMedCentral
101.
Edeling M, Ragi G, Huang S, Pavenstädt H, Susztak K. Developmental signalling pathways in renal fibrosis: the roles of Notch, wnt and hedgehog. Nat Rev Nephrol. 2016;12(7):426–39.PubMedPubMedCentral
102.
103.
di Magliano MP, Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer. 2003;3(12):903–11.
104.
Lin J, Tan H, Nie Y, Wu D, Zheng W, Lin W, et al. Krüppel-like factor 2 inhibits hepatocarcinogenesis through negative regulation of the hedgehog pathway. Cancer Sci. 2019;110(4):1220–31.PubMedPubMedCentral
105.
Morikawa M, Derynck R, Miyazono K. TGF-β and the TGF-β family: context-dependent roles in cell and tissue physiology. Cold Spring Harb Perspect Biol. 2016;8(5):a021873.PubMedPubMedCentral
106.
Derynck R, Budi EH. Specificity, versatility, and control of TGF-β family signaling. Sci Signal. 2019;12(570):eaav5183.PubMedPubMedCentral
107.
David CJ, Massagué J. Contextual determinants of TGFβ action in development, immunity and cancer. Nat Rev Mol Cell Biol. 2018;19(7):419–35.PubMedPubMedCentral
108.
109.
Boon RA, Fledderus JO, Volger OL, Van Wanrooij EJ, Pardali E, Weesie F, et al. KLF2 suppresses TGF-β signaling in endothelium through induction of Smad7 and inhibition of AP-1. Arterioscler Thromb Vasc Biol. 2007;27(3):532–9.PubMed
110.
Yan X, Chen Y-G. Smad7: not only a regulator, but also a cross-talk mediator of TGF-β signalling. Biochem J. 2011;434(1):1–10.PubMed
111.
Chen Y, Yang L. FBXL19-AS1 aggravates the progression of hepatocellular cancer by downregulating KLF2. J BU ON: Official J Balkan Union Oncol. 2021;26(4):1333–9.
112.
Huang M-d, Chen W-m, Qi F-z, Xia R, Sun M, Xu T-p, et al. Long non-coding RNA ANRIL is upregulated in hepatocellular carcinoma and regulates cell proliferation by epigenetic silencing of KLF2. J Hematol Oncol. 2015;8(1):1–14.PubMedPubMedCentral
113.
Jiang H, Shi X, Ye G, Xu Y, Xu J, Lu J, et al. Up-regulated long non-coding RNA DUXAP8 promotes cell growth through repressing Krüppel-like factor 2 expression in human hepatocellular carcinoma. OncoTargets and Therapy. 2019;12:7429.PubMedPubMedCentral
114.
Zou K, Lu X, Ye K, Wang C, You T, Chen J. Krüppel-like factor 2 promotes cell proliferation in hepatocellular carcinoma through up-regulation of c-myc. Cancer Biol Ther. 2016;17(1):20–6.PubMedPubMedCentral
115.
Baker SJ, Reddy EP. CDK4: a key player in the cell cycle, development, and cancer. Genes & cancer. 2012;3(11–12):658–69.
116.
Rea K, Sensi M, Anichini A, Canevari S, Tomassetti A. EGFR/MEK/ERK/CDK5-dependent integrin-independent FAK phosphorylated on serine 732 contributes to microtubule depolymerization and mitosis in tumor cells. Cell Death Dis. 2013;4(10):e815–e.PubMedPubMedCentral
117.
Alarcón C, Zaromytidou A-I, Xi Q, Gao S, Yu J, Fujisawa S, et al. CDK8/9 drive smad transcriptional action, turnover and YAP interactions in BMP and TGFβ pathways. Cell. 2009;139(4):757.PubMedPubMedCentral
118.
Borggrefe T, Davis R, Erdjument-Bromage H, Tempst P, Kornberg RD. A complex of the Srb8,-9,-10, and-11 transcriptional regulatory proteins from yeast. J Biol Chem. 2002;277(46):44202–7.PubMed
119.
Larschan E, Winston F. The Saccharomyces cerevisiae Srb8-Srb11 complex functions with the SAGA complex during Gal4-activated transcription. Mol Cell Biol. 2005;25(1):114–23.PubMedPubMedCentral
120.
Samuelsen CO, Baraznenok V, Khorosjutina O, Spåhr H, Kieselbach T, Holmberg S et al. TRAP230/ARC240 and TRAP240/ARC250 Mediator subunits are functionally conserved through evolution. Proceedings of the National Academy of Sciences. 2003;100(11):6422-7.
121.
Xu W, Wang Z, Zhang W, Qian K, Li H, Kong D, et al. Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/β-catenin signaling pathway. Cancer Lett. 2015;356(2):613–27.PubMed
122.
Chan E, Gat U, McNiff JM, Fuchs E. A common human skin tumour is caused by activating mutations in β-catenin. Nat Genet. 1999;21(4):410–3.PubMed
123.
Dominguez I, Itoh K, Sokol SY. Role of glycogen synthase kinase 3 beta as a negative regulator of dorsoventral axis formation in Xenopus embryos. Proc Natl Acad Sci. 1995;92(18):8498–502.PubMedPubMedCentral
124.
Atkins GB, Jain MK. Role of Kruppel-like transcription factors in endothelial biology. Circul Res. 2007;100(12):1686–95.
125.
Dekker RJ, Boon RA, Rondaij MG, Kragt A, Volger OL, Elderkamp YW, et al. KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium. Blood. 2006;107(11):4354–63.PubMed
126.
Wei R, Kong L, Xiao Y, Yuan H, Song Y, Wang J, et al. CDK8 regulates the angiogenesis of pancreatic cancer cells in part via the CDK8-β-catenin-KLF2 signal axis. Exp Cell Res. 2018;369(2):304–15.PubMed
127.
Zhang D, Dai Y, Cai Y, Suo T, Liu H, Wang Y, et al. KLF2 is downregulated in pancreatic ductal adenocarcinoma and inhibits the growth and migration of cancer cells. Tumor Biology. 2016;37(3):3425–31.PubMed
128.
Lian Y, Wang J, Feng J, Ding J, Ma Z, Li J, et al. Long non-coding RNA IRAIN suppresses apoptosis and promotes proliferation by binding to LSD1 and EZH2 in pancreatic cancer. Tumor Biology. 2016;37(11):14929–37.PubMed
129.
Ma Z, Huang H, Wang J, Zhou Y, Pu F, Zhao Q, et al. Long non-coding RNA SNHG15 inhibits P15 and KLF2 expression to promote pancreatic cancer proliferation through EZH2-mediated H3K27me3. Oncotarget. 2017;8(48):84153.PubMedPubMedCentral
130.
Lian Y, Yang J, Lian Y, Xiao C, Hu X, Xu H. DUXAP8, a pseudogene derived lncRNA, promotes growth of pancreatic carcinoma cells by epigenetically silencing CDKN1A and KLF2. Cancer Commun. 2018;38(1):1–11.
131.
Yuedi D, Houbao L, Pinxiang L, Hui W, Min T, Dexiang Z. KLF2 induces the senescence of pancreatic cancer cells by cooperating with FOXO4 to upregulate p21. Exp Cell Res. 2020;388(1):111784.PubMed
132.
Wang Y, Decker SJ, Sebolt-Leopold J. Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther. 2004;3(3):305–13.PubMed
133.
Elder RT, Yu M, Chen M, Zhu X, Yanagida M, Zhao Y. HIV-1 vpr induces cell cycle G2 arrest in fission yeast (Schizosaccharomyces pombe) through a pathway involving regulatory and catalytic subunits of PP2A and acting on both Wee1 and Cdc25. Virology. 2001;287(2):359–70.PubMed
134.
Rowley R, Hudson J, Young PG. The wee1 protein kinase is required for radiation-induced mitotic delay. Nature. 1992;356(6367):353–5.PubMed
135.
Li R, Chen J, Gao X, Jiang G. Transcription factor KLF2 enhances the sensitivity of breast cancer cells to cisplatin by suppressing kinase WEE1. Cancer Biol Ther. 2021;22(7–9):465–77.PubMedPubMedCentral
136.
Zhu K-Y, Tian Y, Li Y-X, Meng Q-X, Ge J, Cao X-C, et al. The functions and prognostic value of Krüppel-like factors in breast cancer. Cancer Cell Int. 2022;22(1):1–12.
137.
Wang L, Ye T, Wu H, Chen S, Weng J, Xi X. LINC00702 accelerates the progression of ovarian cancer through interacting with EZH2 to inhibit the transcription of KLF2. Eur Rev Med Pharmacol Sci. 2019;23(3 Suppl):201–8.PubMed
138.
Bai Z, Wu Y, Bai S, Yan Y, Kang H, Ma W, et al. Long non-coding RNA SNGH7 is activated by SP1 and exerts oncogenic properties by interacting with EZH2 in ovarian cancer. J Cell Mol Med. 2020;24(13):7479–89.PubMedPubMedCentral
139.
Chen L, Yang H, Xiao Y, Tang X, Li Y, Han Q, et al. Lentiviral-mediated overexpression of long non-coding RNA GAS5 reduces invasion by mediating MMP2 expression and activity in human melanoma cells. Int J Oncol. 2016;48(4):1509–18.PubMed
140.
Huang D, Du X, Yuan R, Chen L, Liu T, Wen C, et al. Rock2 promotes the invasion and metastasis of hepatocellular carcinoma by modifying MMP2 ubiquitination and degradation. Biochem Biophys Res Commun. 2014;453(1):49–56.PubMed
141.
Lu L, Xue X, Lan J, Gao Y, Xiong Z, Zhang H, et al. MicroRNA-29a upregulates MMP2 in oral squamous cell carcinoma to promote cancer invasion and anti-apoptosis. Biomed Pharmacother. 2014;68(1):13–9.PubMed
142.
Wang B, Liu M, Song Y, Li C, Zhang S, Ma L. KLF2 inhibits the migration and invasion of prostate cancer cells by downregulating MMP2. Am J Men’s Health. 2019;13(1):1557988318816907.
143.
Zhu Y, Tong Y, Wu J, Liu Y, Zhao M. Knockdown of LncRNA GHET1 suppresses prostate cancer cell proliferation by inhibiting HIF-1α/Notch‐1 signaling pathway via KLF2. BioFactors. 2019;45(3):364–73.PubMed
144.
Xue P, Yan M, Wang K, Gu J, Zhong B, Tu C. Up-regulation of LINC00665 facilitates the malignant progression of prostate cancer by epigenetically silencing KLF2 through EZH2 and LSD1. Front Oncol. 2021:1165.
145.
Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet. 2012;13(5):343–57.PubMedPubMedCentral
146.
Black JC, Van Rechem C, Whetstine JR. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell. 2012;48(4):491–507.PubMed
147.
Yamane K, Toumazou C, Tsukada Y-i, Erdjument-Bromage H, Tempst P, Wong J, et al. JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell. 2006;125(3):483–95.PubMed
148.
Okada Y, Scott G, Ray MK, Mishina Y, Zhang Y. Histone demethylase JHDM2A is critical for Tnp1 and Prm1 transcription and spermatogenesis. Nature. 2007;450(7166):119–23.PubMed
149.
Loh Y-H, Zhang W, Chen X, George J, Ng H-H. Jmjd1a and Jmjd2c histone H3 lys 9 demethylases regulate self-renewal in embryonic stem cells. Genes Dev. 2007;21(20):2545–57.PubMedPubMedCentral
150.
Kuroki S, Matoba S, Akiyoshi M, Matsumura Y, Miyachi H, Mise N, et al. Epigenetic regulation of mouse sex determination by the histone demethylase Jmjd1a. Science. 2013;341(6150):1106–9.PubMed
151.
Mittrücker H-W, Matsuyama T, Grossman A, Kündig TM, Potter J, Shahinian A, et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science. 1997;275(5299):540–3.PubMed
152.
Sciammas R, Shaffer A, Schatz JH, Zhao H, Staudt LM, Singh H. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity. 2006;25(2):225–36.PubMed
153.
Klein U, Casola S, Cattoretti G, Shen Q, Lia M, Mo T, et al. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol. 2006;7(7):773–82.PubMed
154.
Ohguchi H, Hideshima T, Bhasin MK, Gorgun GT, Santo L, Cea M, et al. The KDM3A–KLF2–IRF4 axis maintains myeloma cell survival. Nat Commun. 2016;7(1):1–15.
155.
Schmidt M, De Mazière A, Smyczek T, Gray A, Parker L, Filvaroff E, et al. editors. The role of Egfl7 in vascular morphogenesis. Novartis Foundation Symposium; 2007: Chichester; New York; John Wiley; 1999.
156.
Nikolić I, Stanković ND, Bicker F, Meister J, Braun H, Awwad K, et al. EGFL7 ligates αvβ3 integrin to enhance vessel formation. Blood the Journal of the American Society of Hematology. 2013;121(15):3041–50.
157.
Hong G, Kuek V, Shi J, Zhou L, Han X, He W, et al. EGFL7: Master regulator of cancer pathogenesis, angiogenesis and an emerging mediator of bone homeostasis. J Cell Physiol. 2018;233(11):8526–37.PubMed
158.
Papaioannou D, Shen C, Nicolet D, McNeil B, Bill M, Karunasiri M, et al. Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia. Proc Natl Acad Sci. 2017;114(23):E4641–E7.PubMedPubMedCentral
159.
Ria R, Vacca A, Ribatti D, Di Raimondo F, Merchionne F, Dammacco F. Alpha (v) beta (3) integrin engagement enhances cell invasiveness in human multiple myeloma. Haematologica. 2002;87(8):836–45.PubMed
160.
Vacca A, Ria R, Presta M, Ribatti D, Iurlaro M, Merchionne F, et al. αvβ3 integrin engagement modulates cell adhesion, proliferation, and protease secretion in human lymphoid tumor cells. Exp Hematol. 2001;29(8):993–1003.PubMed
161.
Tucci M, De Palma R, Lombardi L, Rodolico G, Berrino L, Dammacco F, et al. β3 integrin subunit mediates the bone-resorbing function exerted by cultured myeloma plasma cells. Cancer Res. 2009;69(16):6738–46.PubMed
162.
Nichol D, Shawber C, Fitch MJ, Bambino K, Sharma A, Kitajewski J, et al. Impaired angiogenesis and altered notch signaling in mice overexpressing endothelial Egfl7. Blood. J Am Soc Hematol. 2010;116(26):6133–43.
163.
Salama Y, Heida AH, Yokoyama K, Takahashi S, Hattori K, Heissig B. The EGFL7-ITGB3-KLF2 axis enhances survival of multiple myeloma in preclinical models. Blood Adv. 2020;4(6):1021–37.PubMedPubMedCentral
164.
Wu N, Chen S, Luo Q, Jiang Z, Wang X, Li Y, et al. Kruppel-like factor 2 acts as a tumor suppressor in human retinoblastoma. Exp Eye Res. 2022;216:108955.PubMed
165.
Ruan J, Zheng L, Hu N, Guan G, Chen J, Zhou X, et al. Long noncoding RNA SNHG6 promotes osteosarcoma cell proliferation through regulating p21 and KLF2. Arch Biochem Biophys. 2018;646:128–36.PubMed
Metadata
Title
PRC2 mediated KLF2 down regulation: a therapeutic and diagnostic axis during tumor progression
Authors
Negin Taghehchian
Amirhosein Maharati
Iman Akhlaghipour
Amir Sadra Zangouei
Meysam Moghbeli
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2023
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-023-03086-3

Other articles of this Issue 1/2023

Cancer Cell International 1/2023 Go to the issue

Review

PCIF1, the only methyltransferase of N6,2-O-dimethyladenosine

Review

Metal nanoparticles as a potential technique for the diagnosis and treatment of gastrointestinal cancer: a comprehensive review

Research

NEDD8 promotes radioresistance via triggering autophagy formation and serves as a novel prognostic marker in oral squamous cell carcinoma

Retraction Note

Retraction Note: Targeting a novel LncRNA SNHG15/miR-451/c-Myc signaling cascade is effective to hamper the pathogenesis of breast cancer (BC) in vitro and in vivo

Review

Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages

Review

Role of non-canonical post-translational modifications in gastrointestinal tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits